Virax Biolabs announces extraordinary general meeting of shareholders
VRAX•Virax Biolabs will hold an extraordinary general meeting on November 27, 2026, where shareholders will consider a 1-for-4 share consolidation and a proposal to increase authorized share capital from $12.5 million to $50 million.
1. Meeting proposals
Virax Biolabs will hold the meeting at BioCity Glasgow in Newhouse, Lanarkshire. Shareholders will vote on a 1-for-4 ordinary share consolidation, proposed to take effect on December 14, 2026, or later, and a subsequent increase in authorized share capital to $50 million, creating 375 million ordinary shares. They will also consider related charter amendments and whether to allow adjournment if votes are insufficient to pass the proposals.
